WO2006059346A2 - An improved process for lactonization to produce highly pure statins - Google Patents

An improved process for lactonization to produce highly pure statins Download PDF

Info

Publication number
WO2006059346A2
WO2006059346A2 PCT/IN2005/000392 IN2005000392W WO2006059346A2 WO 2006059346 A2 WO2006059346 A2 WO 2006059346A2 IN 2005000392 W IN2005000392 W IN 2005000392W WO 2006059346 A2 WO2006059346 A2 WO 2006059346A2
Authority
WO
WIPO (PCT)
Prior art keywords
solvents
improved process
water
lactonization
statins
Prior art date
Application number
PCT/IN2005/000392
Other languages
French (fr)
Other versions
WO2006059346A3 (en
Inventor
Sanjay Suri
Tapan Kashyap
Girish Chandra Pundir
Original Assignee
Morepen Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morepen Laboratories Limited filed Critical Morepen Laboratories Limited
Publication of WO2006059346A2 publication Critical patent/WO2006059346A2/en
Publication of WO2006059346A3 publication Critical patent/WO2006059346A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Definitions

  • the present invention particularly relates to a process for lactonization to produce simvastatin. More particularly, the invention relates to a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions. Specifically the process can be carried out at moderate temperature resulting in the title product with purity greater than 99% and dimer impurity to a level of less than 0.05%. Still more particularly, the invention relates to a process for lactonization to produce simvastatin involving using a mixture of carboxylic acid anhydride and water miscible organic solvent. Preferably, the solvent used may be nitrile solvent.
  • statins are well known potent antihypercholesterolemic agents that function by limiting cholesterol biosynthesis by inhibiting the enzyme, HMG-CoA reductase.
  • This class of compounds referred to generally as statins, are produced either by natural fermentation process or through semisynthetic and totally synthetic routes. Two of the most popular compounds in this therapeutic category are Simvastatin and Atorvastatin. The former is one of the most prescribed drugs in the treatment of primary hypercholesterolemia with minimum side effects & well established safety profile.
  • statins of formula II The use of highly pure statins is exceedingly desirable in preparation of pharmaceutical compositions/ formulations as it would avoid accumulation of impurities during prolonged usage and reduce the possible side effects during medical treatment.
  • dihydroxy acid or its salt of formula I is the common intermediate for producing statins of formula II.
  • R is H or CH3 and X ix H or a metal cation or a NH4 cation.
  • lactonization is a process wherein, a dihydroxy acid losses one molecule each of ammonia and water to form an intramolecular ester (lactone).
  • lactone an intramolecular ester
  • the reaction is catalyzed by an acid and a dehydrating agent, Lactonization is an equilibrium process represented, in the case of statins, by the following equation:
  • US patent no. 5,393,893 discloses a process wherein the lactonization is carried out in a two-phase system of an organic system, in which the lactone is soluble, and an aqueous acid, whereby the formed water is displaced from the organic layer containing the lactone, to the aqueous layer.
  • the preferred weak acid is acetic acid and
  • recovering is carried out by using anti-solvent such as hexane, heptane, cyclohexane or water, preferably water.
  • anti-solvent such as hexane, heptane, cyclohexane or water, preferably water.
  • US 20040077884 claims that the process disclosed in this invention yields a product having impurities ⁇ 0.1%.
  • the process comprises lactonizing hydroxy acid salt with a mixture of glacial acetic acid and acetonitrile in anhydrous conditions at a temperature in the range of about 50 to 8O 0 C and precipitating statins by adding water.
  • the invention claims consistent production of simvastatin at moderate temperature with more than 99.5% purity and dimmer content less than 0.1 Vo.
  • the examples illustrate the yield in the range of 89 to 90 %, HPLC purity of 99.55 to 99.63% and dimer impurity of 0,04 to 0.07%.
  • the main change is employing acetonitrile in conjunction with acetic acid and precipitating with water in turn making process user and environment friendly, economic and easy to scale up for commercial manufacture.
  • the mechanism in this process, as described relates to removal of ammonia formed, as a by-product, using mixture of acetic acid and acitonitrile however, it is unable to remove water which is also formed as a by-product of lactonisation reaction.
  • the reaction gets completed in about five to seven hours.
  • the amount of acetic acid used is at least three to five parts by volume per part of starting material and the amount acitonitrile used is 10 to 20 parts by volume preferably 15 parts by volume of the starting material.
  • the process also claims an advantage of easy isolation by addition of water.
  • the main aim of the present invention is to provide a process of lactonization to produce highly pure statins.
  • the other object of the present invention is to provide a process for lactonization to produce simvastatin.
  • Another object of the present invention is to provide a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions thereby making the process environment friendly on industrial scale.
  • Yet other object of the present invention is to provide a process that can be carried out at moderate temperature resulting in the title product with higher yield and purity.
  • statin of formula II by conventional methods optionally purifying the said title compound employing ethyl acetate and hexane for recrystallisation wherein (a) the solvent used is nitrile solvents, ketonic solvents, hydrocarbon solvents, ethereal solvents, ester solvents and/or halogenated solvents and (b) recovery of statins is conducted by adding water proviso the solvent used is water miscible or by conventional crystallization method in case solvent used is water immiscible.
  • the reaction is performed in presence of a stabilizer like butylated hydroxyl toluene, butylated hydroxyl anisole.
  • the carboxylic acid anhydride employed may be such as acetic anhydride or propionic anhydride.
  • the laconization may be performed at a temperature of 10-40° C and typically for a period of 5 to 30 hours.
  • Solvents used may be nitrile solvents like acetonitrile, propionitrile; ketonic solvents like acetone, methyl isobutyl ketone, methyl ethyl ketone; hydrocarbon solvents like hexanes, heptanes, cyclohexane, benzene, toluene, xylenes; ester solvents like, ethyl acetate; ether solvents like, diethyl ether, diisopropyl ether, tetrahydrofuran and halogenated solvents like dichloromethane, chloroform.
  • the amount of acid anhydride used is 1 to 5 parts by volume per part of the starting material.
  • EXAMPLE l Simvastatin ammonium salt (50 g) of formula I is reacted with acetic anhydride (125 g) in acetonitrile (750 ml) at 20-25 0 C for 20-25 hours. Reaction mass is cooled and water is added slowly to bring about crystallization of the product. Slurry is filtered and washed with water followed by drying of the cake to yield 45 g of Simvastatin, which is purified to give the final Simvastatin having dimer impurity ⁇ 0.05%.
  • acetic anhydride 125 g
  • acetonitrile 750 ml
  • Simvastatin ammonium salt (50g) of formula 1 is reacted with acetic anhydride (75g) in

Abstract

This invention describes a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions. Specifically the process can be carried out at moderate temperature resulting in statins particularly simvastatin with purity greater than 99% and dimer impurity to a level of less than 0.05%. The process involves using a mixture of carboxylic acid anhydride and water miscible organic solvent. Specifically, the reagents used may be acetic anhydride and acetonitrile. The statin is precipitated using water and further purified if so desired.

Description

AN IMPROVED PROCESS FOR LACTOMZATION TO PRODUCE HIGHLY PURE STATINS.
FIELD OF THE INVENTION:
The present invention particularly relates to a process for lactonization to produce simvastatin. More particularly, the invention relates to a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions. Specifically the process can be carried out at moderate temperature resulting in the title product with purity greater than 99% and dimer impurity to a level of less than 0.05%. Still more particularly, the invention relates to a process for lactonization to produce simvastatin involving using a mixture of carboxylic acid anhydride and water miscible organic solvent. Preferably, the solvent used may be nitrile solvent.
BACKGROUND OF THE INVENTIQN- Lovastatin, Simvastatin, Pravastatin, Atorvastatin, and Mevastatin are well known potent antihypercholesterolemic agents that function by limiting cholesterol biosynthesis by inhibiting the enzyme, HMG-CoA reductase. This class of compounds, referred to generally as statins, are produced either by natural fermentation process or through semisynthetic and totally synthetic routes. Two of the most popular compounds in this therapeutic category are Simvastatin and Atorvastatin. The former is one of the most prescribed drugs in the treatment of primary hypercholesterolemia with minimum side effects & well established safety profile. The use of highly pure statins is exceedingly desirable in preparation of pharmaceutical compositions/ formulations as it would avoid accumulation of impurities during prolonged usage and reduce the possible side effects during medical treatment. In most of the preparative methods dihydroxy acid or its salt of formula I is the common intermediate for producing statins of formula II.
Figure imgf000003_0001
II
Where R is H or CH3 and X ix H or a metal cation or a NH4 cation.
The above common intermediate is cyclized making lactonization as an essential step of the synthesis. The lactonization of ammonium compound I is a process wherein, a dihydroxy acid losses one molecule each of ammonia and water to form an intramolecular ester (lactone). The reaction is catalyzed by an acid and a dehydrating agent, Lactonization is an equilibrium process represented, in the case of statins, by the following equation:
Dihydroxy acid ammonium salt <===> Lactone + Water + Ammonia. In order to obtain high yield of the lactone, it is necessary to remove water and ammonia ■from the reaction mass to shift the equilibrium towards right. Thus, The main problem associated with lactonization is to shift the equilibrium to lactone side in order to yield statins with high purity and yield.
One known way is the physical removal of produced water from the reaction mixture, e.g. by means of azeotropic distillation. The other problem is the formation of dimeric impurity. Statins are sensitive to heating and so the use of elevated temperatures for laconization gives rise to the risk of impurities being formed. One of the most common impurities is dimer of formula III, which arises from dimerization of the starting material where in R is H or CH3..
Figure imgf000004_0001
III The prior art known to the inventor includes US 4,820,850 ('85O). The process described in patent '850 involves heating the free acid or its salt preferably ammonium salt to reflux
temperature, usually = 1000C in high boiling inert hydrocarbon solvent such as toluene
for 7 to 8 hours in presence of strong acid catalyst. The ambient acidty of the acid is believed to be responsible for lactonization. The process results in high-level impurity of dimmer. Further, the process is cost extensive due to high dilution requirements and thus not feasible for industrial operation. The shift in equilibrium was achieved by continuously removing water by azeotropic distillation. Removal of ammonia may be increased by passing a stream of inert gas through the hot reaction mixture
US patent no. 5,393,893, discloses a process wherein the lactonization is carried out in a two-phase system of an organic system, in which the lactone is soluble, and an aqueous acid, whereby the formed water is displaced from the organic layer containing the lactone, to the aqueous layer.
US patent 4, 916, 239 ('239) teaches reacting hydroxy acid salt at ambient temperature with a mixture of water miscible organic solvent and strong acid catalyst under inert atmosphere. According to this process continuous and selective removal of lactone by adding water gradually to effect crystallization of lactone helps in shifting equilibrium. Further using water miscible organic solvent enables selective solubility of desired compound. The process claims to reduce the level of impurities to < 0.2% as against 0.4 to 0.8% present in the product produced by the prior art. The process is associated with disadvantages such as using strong acid catalyst and addition of water in controlled manner making the process cost extensive and difficult to operate on industrial scale. Moreover, though the process claims use of water miscible organic solvent, the description only supports to using acetic acid. US 5,917,058 ('058) advocates eliminating using strong acid catalyst performing Iactonization at ambient temperature there by eliminating problems arising through strong acid catalyst. According to the process disclosed in this invention, hydroxy acid salt is reacted with weak organic acid in absence of strong acid catalyst below temperature of
550C and recovering title compound. The preferred weak acid is acetic acid and
recovering is carried out by using anti-solvent such as hexane, heptane, cyclohexane or water, preferably water. The yield of the product as exemplified ranges from 87% to 95% and purity of the compound obtained varies from >95% to>98%.
US 20040077884 ('884) claims that the process disclosed in this invention yields a product having impurities < 0.1%. The process comprises lactonizing hydroxy acid salt with a mixture of glacial acetic acid and acetonitrile in anhydrous conditions at a temperature in the range of about 50 to 8O0C and precipitating statins by adding water.
The invention claims consistent production of simvastatin at moderate temperature with more than 99.5% purity and dimmer content less than 0.1 Vo. The examples illustrate the yield in the range of 89 to 90 %, HPLC purity of 99.55 to 99.63% and dimer impurity of 0,04 to 0.07%. The main change is employing acetonitrile in conjunction with acetic acid and precipitating with water in turn making process user and environment friendly, economic and easy to scale up for commercial manufacture. The mechanism in this process, as described relates to removal of ammonia formed, as a by-product, using mixture of acetic acid and acitonitrile however, it is unable to remove water which is also formed as a by-product of lactonisation reaction. Typically the reaction gets completed in about five to seven hours. The amount of acetic acid used is at least three to five parts by volume per part of starting material and the amount acitonitrile used is 10 to 20 parts by volume preferably 15 parts by volume of the starting material. The process also claims an advantage of easy isolation by addition of water.
After continuous research, we discovered that use of carboxylic acid anhydride in combination with nitrile helps in removal of both the by-products of lactonisation process i.e. water and ammonia. Under the conditions selected for the present process the reaction byproduct water reacts with anhydride and converts the same to respective acid which in turns consume another by-product i.e. ammonia. Ammonium salt thus, produced further helps in gradual removal of water and helps continuously shifting the equilibrium to lactone side in a sustained manner and in turn helps completion of reaction. Thus, the process of the present invention become more advantageous over the one disclosed herein above. Further, the dimeric impurity level is reduced to less than 0.05%, which meets the ICH guidelines and makes the title product highly pure. SUMMARY OF THE INVENTION
The main aim of the present invention is to provide a process of lactonization to produce highly pure statins. The other object of the present invention is to provide a process for lactonization to produce simvastatin. Another object of the present invention is to provide a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions thereby making the process environment friendly on industrial scale. Yet other object of the present invention is to provide a process that can be carried out at moderate temperature resulting in the title product with higher yield and purity.
Yet another object of the present invention is to provide a process for lactonization to produce simvastatin with reduced dimeric impurity to a level of less than 0.05%. Still other object of the present invention is to provide a process for lactonization to produce simvastatin involving using a mixture of carboxylic acid anhydride and water miscible organic solvent. Specifically, the solvent used may be nitrile solvent Still another object of the present invention is to provide a process for lactonization to produce simvastatin that is convenient to operate on commercial scale. STATEMENT OF INVENTION: According to this invention, there is provided an improved process for lactonization to
produce highly pure statins of Formula II, where in R is H or CH3
Figure imgf000007_0001
I II comprising lactonization of compound of Formula I where R is H or CH3 and X is H, a
metal cation or NH4 cation in a mixture of an organic solvent and carboxylic acid anhydride under anhydrous condition and recovering the statin of formula II by conventional methods optionally purifying the said title compound employing ethyl acetate and hexane for recrystallisation wherein (a) the solvent used is nitrile solvents, ketonic solvents, hydrocarbon solvents, ethereal solvents, ester solvents and/or halogenated solvents and (b) recovery of statins is conducted by adding water proviso the solvent used is water miscible or by conventional crystallization method in case solvent used is water immiscible.
The reaction is performed in presence of a stabilizer like butylated hydroxyl toluene, butylated hydroxyl anisole.
The carboxylic acid anhydride employed may be such as acetic anhydride or propionic anhydride. The laconization may be performed at a temperature of 10-40° C and typically for a period of 5 to 30 hours.
Solvents used may be nitrile solvents like acetonitrile, propionitrile; ketonic solvents like acetone, methyl isobutyl ketone, methyl ethyl ketone; hydrocarbon solvents like hexanes, heptanes, cyclohexane, benzene, toluene, xylenes; ester solvents like, ethyl acetate; ether solvents like, diethyl ether, diisopropyl ether, tetrahydrofuran and halogenated solvents like dichloromethane, chloroform.
The amount of acid anhydride used is 1 to 5 parts by volume per part of the starting material. The amount of solvent is 2 to 20 parts by volume per part of the starting material. Crystallization of the title product from reaction mass may be conducted using alkanolic solvents like C1-C5 alkanols, water or a mixture thereof
Major advantages of the present invention as compared to the prior art procedures are: 1) The product obtained is highly pure having dimer impurity reduced to fairly less than 0.05%. 2) No corrosive acids and solvent immiscible solid reagents are used, which complicate the operations of filtration etc.
3) Volumes of reactants and solvents are greatly reduced.
4) The process is very easy to operate at large scale, cost efficient and environment friendly. 5) Work up and product isolation procedure is very simple and easy and does not require any special infrastructure of plant and machinery.
The process is further illustrated by non limiting examples, which should not restrict scope of the invention.
EXAMPLE l : Simvastatin ammonium salt (50 g) of formula I is reacted with acetic anhydride (125 g) in acetonitrile (750 ml) at 20-250C for 20-25 hours. Reaction mass is cooled and water is added slowly to bring about crystallization of the product. Slurry is filtered and washed with water followed by drying of the cake to yield 45 g of Simvastatin, which is purified to give the final Simvastatin having dimer impurity <0.05%. EXAMPLE:
Simvastatin ammonium salt (50g) of formula 1 is reacted with acetic anhydride (75g) in
250 ml acetonitrile at 20 to 25°C for 5 to 15 hours. Reaction mass is cooled and water is
added slowly to bring out crystallization of the title product. The slurry is filtered and washed with water followed by drying to isolate the product. Dried product thus obtained is dissolved in ethyl acetate and recrystallized with n-hexane. The recrystallized product is further charcolized in methanol and water is added slowly to facilitate crystallization of highly pure product having purity of more than 99% and dimeric impurity of less than 0.05%.

Claims

WE CLAIM:
1. An improved process for lactonization to produce highly pure statins of Formula
II, where in R is H or CH3
Figure imgf000010_0001
I II
comprising lactonization of compound of Formula I where R is H or CH3 and X
is H, a metal cation or NH4 cation in a mixture of an organic solvent and carboxylic acid anhydride under anhydrous condition and recovering the statin of formula II by conventional methods optionally purifying the said title compound employing ethyl acetate and hexane for recrystallisation; wherein (a) the solvent used is nitrile solvents, ketonic solvents, hydrocarbon solvents, ethereal solvents, ester solvents and/or halogenated solvents and (b) recovery of statins is conducted by adding water proviso the solvent used is water miscible or by conventional crystallization method in case solvent used is water immiscible.
2, An improved process as claimed in claim 1 wherein the reaction is performed in presence of a stabilizer like butylated hydroxyl toluene, butylated hydroxyl anisole.
3, An improved process as claimed in previous claims wherein the carboxylic acid anhydride employed is acetic anhydride or propionic anhydride.
4. An improved process as claimed in previous claims wherein the laconization may be performed at a temperature of 10-40° C and typically for a period of 5 to 30 hours.
5. An improved process as claimed in previous claims wherein the solvents used are nitrile solvents like acetonitrile, propionitrile; ketonic solvents like acetone, methyl isobutyl ketone, methyl ethyl ketone; hydrocarbon solvents like hexanes, heptanes, cyclohexane, benzene, toluene, xylenes; ester solvents like, ethyl acetate; ether solvents like, diethyl ether, diisopropyl ether, tetrahydrofuran and halogenated solvents like dichloromethane, chloroform.
6. An improved process as claimed in previous claims wherein the amount of acid anhydride used is 1 to 5 parts by volume per part of the starting material. The amount of solvent is 2 to 20 parts by volume per part of the starting material.
7. An improved process as claimed in previous claims wherein the crystallization of the title product from reaction mass is conducted using alkanolic solvents like Cl- C5 alkanols, water or a mixture thereof.
PCT/IN2005/000392 2004-12-01 2005-11-30 An improved process for lactonization to produce highly pure statins WO2006059346A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2401/DEL/2004 2004-12-01
IN2401DE2004 2004-12-01

Publications (2)

Publication Number Publication Date
WO2006059346A2 true WO2006059346A2 (en) 2006-06-08
WO2006059346A3 WO2006059346A3 (en) 2006-09-08

Family

ID=36565443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000392 WO2006059346A2 (en) 2004-12-01 2005-11-30 An improved process for lactonization to produce highly pure statins

Country Status (1)

Country Link
WO (1) WO2006059346A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009114121A (en) * 2007-11-06 2009-05-28 Kaneka Corp Method for producing simvastatin
CN101381356B (en) * 2008-10-23 2012-05-23 河北科技大学 Preparation method of simvastatin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5917058A (en) * 1997-10-28 1999-06-29 Ranbaxy Laboratories Limited Process of lactonization in the preparation of statins
US20040077884A1 (en) * 2001-05-18 2004-04-22 Ramesh Dandala Process for lactonization to produce highly pure simvastatin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5917058A (en) * 1997-10-28 1999-06-29 Ranbaxy Laboratories Limited Process of lactonization in the preparation of statins
US20040077884A1 (en) * 2001-05-18 2004-04-22 Ramesh Dandala Process for lactonization to produce highly pure simvastatin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009114121A (en) * 2007-11-06 2009-05-28 Kaneka Corp Method for producing simvastatin
CN101381356B (en) * 2008-10-23 2012-05-23 河北科技大学 Preparation method of simvastatin

Also Published As

Publication number Publication date
WO2006059346A3 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
KR100407758B1 (en) Process of lactonization in the preparation of statins
JP2003525935A (en) Method for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
JP2011236212A (en) Process for preparing statin
WO2006059346A2 (en) An improved process for lactonization to produce highly pure statins
CA2780183C (en) A method for preparing a statin compound by lactonization
US6825362B2 (en) Process for lactonization to produce highly pure simvastatin
KR100423892B1 (en) A new process of lactonization in the preparation of statins
CA2540068C (en) A method for the manufacture of lovastatin
JP2004520444A5 (en)
CA2571379C (en) An improved process for lactonization in the preparation of statins
NZ552342A (en) An improved process for lactonization in the preparation of statins
ZA200303734B (en) A lactonization process.
GB2358859A (en) Synthesis of isosorbide compounds
MX2007009422A (en) Process for manufacture of simvastatin.
WO2007086559A1 (en) Method for producing tetrahydropyran compound
KR20000021998A (en) Process for preparing simvastatin and intermediate compound thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05824492

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05824492

Country of ref document: EP

Kind code of ref document: A2